Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4978477 | 0.95 | KDR (0.52) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4978713 | 0.93 | KDR (0.52) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4978687 | 0.93 | KDR (0.51) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14263458 | 0.91 | KDR (0.55) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4976937 | 0.91 | KDR (0.58) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4981704 | 0.90 | KDR (0.53) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4980512 | 0.89 | KDR (0.52) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4982096 | 0.88 | KDR (0.55) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4980501 | 0.87 | KDR (0.52) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4978947 | 0.87 | KDR (0.57) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7338959-B2 | Diamino-pyrimidines and their use as angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-04 | — | — | US | claimed |
| US-20050234083-A1 | Diamino-pyrimidines and their use as angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-10-20 | — | — | US | claimed |
| US-7338959-B2 | Diamino-pyrimidines and their use as angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-20050234083-A1 | Diamino-pyrimidines and their use as angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234083-A1 | Diamino-pyrimidines and their use as angiogenesis inhibitors | TIE1, TEK, KDR | KDR 3/4885CYP3A4 3874/4885CYP2D6 3399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.